12 reports

  • GROWING APPROVALS IN LUNG CANCER THERAPEUTICS MARKET
  • MARKET PENETRATION OF VARIOUS LUNG CANCER THERAPEUTICS MANUFACTURERS IN GLOBAL (2015)

About Lung Cancer Therapeutics Lung cancer is a common cause of mortality and morbidity in both developed and developing countries. Smoking is a major cause of lung cancer, though it also occurs in non-smokers. Lung cancer can be categorized into two major types, namely NSCLC and SCLC. NSCLC is the commonest type of lung cancer and constitutes...

  • Cancer
  • Lung Cancer
  • Therapy
  • AstraZeneca PLC
  • Hoffmann-La Roche Inc.
  • Scope of the report

Roche is one of the major players in the market.

  • Cancer
  • Cervical Cancer
  • Therapy
  • Vaccine
  • Hoffmann-La Roche Inc.
  • LIST OF PHASE III PIPELINE MOLECULES

About Cancer Monoclonal Antibodies The mAbs, which are produced by genetic engineering, target antigens in cells, tissues, and organs. They are used in clinical applications to treat diseases with excellent efficacy and minimal side effects. Their MOA, absence of generic pathway, and therapeutic applications distinguish them from other...

  • Cancer
  • Monoclonal Antibody
  • Therapy
  • Amgen Inc.
  • Hoffmann-La Roche Inc.
  • 08.4 HER-2 POSITIVE BREAST CANCER MARKET IN EU
  • 07. Pipeline Analysis

About HER-2 Positive Breast Cancer Breast cancer is characterized by uncontrolled growth of cancerous cells in the breast. It occurs in both males and females, however, the incidence of breast cancer in males is rare. Histologically, breast cancer can be classified into ductal carcinoma, lobular carcinoma, nipple cancer, and other undifferentiated...

  • Breast Cancer
  • Cancer
  • Therapy
  • Celgene Corporation
  • Hoffmann-La Roche Inc.
  • 7.5 HOFFMANN-LA ROCHE LTD- PRODUCT PORTFOLIO

The global cancer therapy market is expected to register a CAGR of 6.5% during the forecast period, 2018 to 2023. North America dominates the market, due to growing prevalence of cancer diseases and rapid adoption of new therapy and novel drugs in the region. High Prevalence and Incidence of Cancer Disease Worldwide Cancer is...

  • Cancer
  • North America
  • United States
  • Market Size
  • Hoffmann-La Roche Inc.
  • Zarour HM, et al. (2003). Categories of tumor antigens. Cancer Medicine; 6th Edition
  • 8.1 REFERENCES

Global Cancer Immunotherapies Market to 2024 - Increased Uptake of Immune Checkpoint Inhibitors Driving Growth, Supported by a Large, Robust Pipeline Summary Cancer immunotherapy, which can predominantly be classed as a form of targeted therapy, drives an immune response against cancer cells. This...

  • Cancer
  • Cancer Immunotherapy
  • Therapy
  • Hoffmann-La Roche Inc.
  • Idera Pharmaceuticals, Inc.

In the case of node-negative cancers, cancer should be estrogen receptors (ER), progesterone receptor (PR) negative, or associated with one high-risk feature.

  • Cancer
  • United States
  • World
  • Market Size
  • Hoffmann-La Roche Inc.

In the case of node-negative cancers, cancer should be estrogen receptors (ER), progesterone receptor (PR) negative, or associated with one high-risk feature.

  • Cancer
  • United States
  • World
  • Market Size
  • Hoffmann-La Roche Inc.

SGN-LIV##A: This product candidate targets LIV-##, which is active in breast cancer.

  • Cancer
  • Therapy
  • Hoffmann-La Roche Inc.
  • Seattle Genetics, Inc.
  • Takeda Pharmaceutical Company Limited

HOFFMANN-LA ROCHE ENTERED INTO AN AGREEMENT OF WORTH $## BILLION WITH NEWLINK TO DEVELOP THE CANCER DRUG, NLG##.

  • Cancer
  • Monoclonal Antibody
  • Therapy
  • Amgen Inc.
  • Hoffmann-La Roche Inc.
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018
  • Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Idera Pharmaceuticals, Inc.
  • Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development
  • Toll Like Receptor 8 (CD288 or TLR8) - Dormant Products

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Idera Pharmaceuticals, Inc.